miRNA 的進展：一項技術評估

基於 RNA 的治療和診斷研究的加速以及人類基因組測序的進步，使人們對 miRNA 在生物通路中的作用以及治療和診斷應用的潛力有了更深入的了解。. miRNA 診斷的成功臨床驗證為 miRNA 診斷製造商創造了許多機會。 miRNA 作為循環生物標誌物的功能能夠從體液中進行診斷。正在探索 miRNA 生物標誌物在識別甲狀腺癌、乳腺癌和卵巢癌等疾病方面的潛力。 miRNA 診斷技術進一步發展，被視為有前景的即時診斷技術。

本報告將重點關注 miRNA 治療和診斷的發展。我們還探討了推動 miRNA 研究興趣的因素以及影響 miRNA 治療和診斷學商業化的因素，同時還討論了 miRNA 技術公司的新機遇，並為行業和利益相關者提供見解。總結您的投資前景。

內容

戰略要務

• 為什麼增長變得越來越困難，戰略勢在必行 8(TM)：miRNA 技術增長驅動力
• 戰略要務
• 三大戰略要務對 miRNA 行業的影響
• 增長機會加速增長管道引擎

增長機會分析

• 分析範圍
• 細分
• 增長驅動力
• 抑制增長的因素

評估 miRNA 治療前景：簡介

評估 miRNA 治療前景：應用

評估 miRNA 治療前景：遞送和穩定性

miRNA 診斷領域的評估：簡介

miRNA 診斷領域的評估：應用

評估 miRNA 治療和診斷：資金前景

增長機會

• 增長機會 1：改進靶向給藥系統以減少脫靶效應和毒性
• 增長機會 2：開發 POC 診斷技術以檢測跨疾病的循環生物標誌物
• 增長機會 3：精準醫療的伴隨診斷

附錄

下一步

Developments in miRNA sequencing and analysis are driving future growth potential in therapeutics and diagnostics

Accelerated research around RNA-based therapeutics and diagnostics, accompanied by technology advancements in sequencing the human genome, has resulted in a better understanding of the role of miRNA in biological pathways, enhancing its potential in both therapeutics and diagnostics. The successful clinical validation of miRNA diagnostic tests has created several opportunities for miRNA diagnostic companies. The role of miRNAs as circulating biomarkers makes it possible to perform diagnostics from body fluids. The potential of miRNA biomarkers in identifying diseases like thyroid cancer, breast cancer, and ovarian cancer is being explored. miRNA diagnostics is expected to grow further and become prominent in point-of-care diagnostics. The development of miRNA therapeutics has had its challenges with respect to stability and delivery issues. However, newer approaches in the development of antagomiRs (miRNA inhibiting drugs) and agomiRs (miRNA replacement therapy) have shown promising results. miRNA companies have witnessed a highly competitive ecosystem and have been acquired by several larger pharma and diagnostics companies upon their entry into the clinical trial stage.

This study focuses on the developments in miRNA therapeutics and diagnostics. It identifies the factors driving interest in miRNA research as well as those affecting the commercialization of miRNA therapeutics and diagnostics. The report also discusses the emerging opportunities for miRNA technology companies and highlights investment prospects for industry participants and stakeholders.

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on miRNA Technology Growth
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Micro Ribonucleic Acid (miRNA) Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation
• Growth Drivers
• Growth Restraints

Assessment of miRNA Therapeutics Landscape: Introduction

• Emerging Trends in miRNA Therapeutics and Diagnostics
• Increasing Research in miRNA Therapeutics and Diagnostics
• miRNA Drugs Experiencing Rapid Strides in Clinical Development
• Enablers Accelerating miRNA Research and Commercial Development
• Introduction to miRNA Therapeutics
• miRNA Therapeutics to Address Complex Diseases
• Evolving Approaches in Developing Antagomirs and miRNA Mimics
• Structural Modifications to Increase miRNA Stability

Assessment of miRNA Therapeutics Landscape: Application

• Application of miRNAs in Diseases
• Oncology
• Respiratory Diseases
• Neurology
• Cardiovascular Diseases
• Other Diseases
• Other Diseases
• miRNA Therapeutics in Development by Companies
• Increasing miRNA Research Activities in Academia

Assessment of miRNA Therapeutics Landscape: Delivery and Stability

• Challenges in miRNA Therapeutics
• Important miRNA Therapeutics Delivery Systems
• Comparison of miRNA Delivery Systems
• Developing Newer Delivery Systems
• Future Prospects of miRNA Therapeutics

Assessment of miRNA Diagnostics Landscape: Introduction

• Introduction to miRNA Diagnostics
• Benefits of miRNA Diagnostics
• Opportunities for Using miRNA in Diagnostics
• Emerging Developments in miRNA Diagnostics

Assessment of miRNA Diagnostics Landscape: Application

• Oncology
• Neurological Diseases
• Cardiovascular and Other Diseases

Assessment of miRNA Therapeutics & Diagnostics: Funding Landscape

• M&A miRNA Therapeutics
• M&A miRNA Diagnostics
• Funding Landscape of miRNA companies
• miRNA-Important Takeaways
• miRNA-Important Takeaways

Growth Opportunity Universe

• Growth Opportunity 1: Improved Targeted Delivery Systems to Reduce Off-target Effects and Toxicity
• Growth Opportunity 1: Improved Targeted Delivery Systems to Reduce Off-target Effects and Toxicity (continued)
• Growth Opportunity 2:Development of POC Diagnostics to Detect Circulating Biomarkers Across Diseases
• Growth Opportunity 2: Development of POC Diagnostics to Detect Circulating Biomarkers Across Diseases (continued)
• Growth Opportunity 3: Companion Diagnostics for Precision Medicine
• Growth Opportunity 3: Companion Diagnostics for Precision Medicine (continued)

Appendix

• Technology Readiness Levels (TRL): Explanation
• Funding Landscape for miRNA Therapeutics
• Funding Landscape for miRNA Therapeutics (continued)
• Funding Landscape for miRNA Diagnostics

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer